Details for New Drug Application (NDA): 218640
✉ Email this page to a colleague
The generic ingredient in LUBIPROSTONE is lubiprostone. There are ten drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
Summary for 218640
| Tradename: | LUBIPROSTONE |
| Applicant: | Ascent Pharms Inc |
| Ingredient: | lubiprostone |
| Patents: | 0 |
Pharmacology for NDA: 218640
| Mechanism of Action | Chloride Channel Activators |
Medical Subject Heading (MeSH) Categories for 218640
Suppliers and Packaging for NDA: 218640
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 218640 | ANDA | Camber Pharmaceuticals, Inc. | 31722-403 | 31722-403-60 | 60 CAPSULE in 1 BOTTLE (31722-403-60) |
| LUBIPROSTONE | lubiprostone | CAPSULE;ORAL | 218640 | ANDA | Camber Pharmaceuticals, Inc. | 31722-404 | 31722-404-60 | 60 CAPSULE in 1 BOTTLE (31722-404-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 8MCG | ||||
| Approval Date: | Jan 2, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 24MCG | ||||
| Approval Date: | Jan 2, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
